Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#363 of 449

Michael Petusky

Barrington Research · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Aug 2025

Analyst rating accuracy & track record

Michael Petusky is an equity research analyst at Barrington Research. Quantellect has scored 61 of their stock calls across 10 companies. Their picks beat their sector 31% of the time over the next 12 months, and their price targets were reached 47% of the time within a year.

Win % vs sector
31%
PT Hit % (12mo)
47%
Avg sector-excess
−16.7%
Scored calls
61
Tickers
10
Tier
Provisional

Track record

Quantellect has scored 61 of Michael Petusky's stock calls across 10 companies, dating back to 2022. Their rated stocks beat their own sector 31% of the time over the next 12 months. On a typical call, a Petusky pick returned −16.7% more than its sector over the following year.

Of the scored calls, 61 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
VRMEVerifyMe Inc
Buy$1.50Aug 2025−53.1%Hit
HAEHaemonetics Corporation
Buy$86.00Aug 2025+34.1%Hit
USPHU.S. Physical Therapy, Inc.
Buy$103.00Aug 2025−34.3%Miss
XRAYDentsply Sirona Inc
Buy$18.00Aug 2025−35.3%Miss
HSICHenry Schein Inc
Buy$78.00Aug 2025+4.8%Hit
LMATLeMaitre Vascular Inc
Buy$95.00Aug 2025−42.6%Hit
ANIKAnika Therapeutics Inc
Buy$15.00Jul 2025+97.6%Hit
XRAYDentsply Sirona Inc
Buy$21.00Jul 2025−37.6%Miss
HAEHaemonetics Corporation
Buy$95.00Jul 2025−20.8%Miss
OPCHOption Care Health Inc
Buy$38.00Jul 2025−48.3%Miss
USPHU.S. Physical Therapy, Inc.
Buy$98.00Jul 2025−28.8%Miss
OFIXOrthofix Medical Inc
Buy$16.00Jun 2025−32.3%Hit
ANIKAnika Therapeutics Inc
Buy$19.00May 2025+5.7%Miss
XRAYDentsply Sirona Inc
Buy$21.00May 2025−43.8%Miss
OPKOpko Health Inc
Buy$2.25May 2025−27.2%Miss
OPCHOption Care Health Inc
Buy$38.00Apr 2025−45.6%Miss
OPCHOption Care Health Inc
Buy$38.00Apr 2025−21.0%Miss
ANIKAnika Therapeutics Inc
Buy$20.00Mar 2025−15.9%Miss
OPKOpko Health Inc
Buy$2.25Mar 2025−38.8%Miss
VRMEVerifyMe Inc
Buy$1.25Mar 2025+5.9%Hit
OPKOpko Health Inc
Buy$2.25Feb 2025−37.0%Miss
USPHU.S. Physical Therapy, Inc.
Buy$98.00Feb 2025−1.1%Miss
OPCHOption Care Health Inc
Buy$38.00Feb 2025−12.6%Miss
OPCHOption Care Health Inc
Buy$33.00Jan 2025+9.2%Hit
USPHU.S. Physical Therapy, Inc.
Buy$108.00Nov 2024−34.2%Miss
VRMEVerifyMe Inc
Buy$1.50Nov 2024−29.2%Hit
OPKOpko Health Inc
Buy$2.25Nov 2024−15.7%Miss
USPHU.S. Physical Therapy, Inc.
Buy$108.00Nov 2024−19.6%Miss
ANIKAnika Therapeutics Inc
Buy$25.00Nov 2024−42.6%Miss
LMATLeMaitre Vascular Inc
Buy$93.00Nov 2024−9.2%Hit
ANIKAnika Therapeutics Inc
Buy$37.00Oct 2024−59.7%Miss
USPHU.S. Physical Therapy, Inc.
Buy$108.00Oct 2024+21.1%Miss
LMATLeMaitre Vascular Inc
Buy$92.00Sep 2024+11.8%Hit
OPKOpko Health Inc
Buy$2.25Sep 2024+5.9%Miss
USPHU.S. Physical Therapy, Inc.
Buy$108.00Sep 2024+8.2%Miss
USPHU.S. Physical Therapy, Inc.
Buy$108.00Aug 2024+13.5%Miss
VRMEVerifyMe Inc
Buy$1.50Aug 2024−43.5%Hit
ANIKAnika Therapeutics Inc
Buy$37.00Aug 2024−55.9%Miss
OPKOpko Health Inc
Buy$2.25Aug 2024−4.9%Miss
LMATLeMaitre Vascular Inc
Buy$92.00Aug 2024+13.6%Hit
VRMEVerifyMe Inc
Buy$1.70May 2024−70.0%Hit
VRMEVerifyMe Inc
Buy$2.00May 2024−74.8%Hit
ANIKAnika Therapeutics Inc
Buy$37.00May 2024−48.5%Miss
USPHU.S. Physical Therapy, Inc.
Buy$122.00May 2024−22.8%Miss
LMATLeMaitre Vascular Inc
Buy$79.00May 2024+8.8%Hit
OPKOpko Health Inc
Buy$1.50Apr 2024+21.9%Hit
VRMEVerifyMe Inc
Buy$1.70Mar 2024−52.2%Hit
ANIKAnika Therapeutics Inc
Buy$37.00Mar 2024−38.7%Miss
USPHU.S. Physical Therapy, Inc.
Buy$122.00Mar 2024−27.2%Miss
LMATLeMaitre Vascular Inc
Buy$69.00Feb 2024+40.6%Hit
Prev1
Go to

Michael Petusky: analyst track record FAQ

Is Michael Petusky a good stock analyst?

Yes, by track record. Michael Petusky ranks number 363 of 449 of the analysts Quantellect scores, with a Q Score of 0 out of 100. Past results do not guarantee future ones.

What is Michael Petusky's win rate?

Michael Petusky's win rate is 31%. Across 61 scored calls, their rated stocks beat their sector 31% of the time over the next 12 months. On a typical call they returned −16.7% more than the sector.

What stocks and sectors does Michael Petusky cover?

Michael Petusky covers 10 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Michael Petusky's price targets accurate?

Michael Petusky's price targets are reached within 12 months 47% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Michael Petusky's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Michael Petusky rank among Wall Street analysts?

Michael Petusky ranks number 363 of 449 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.